BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17362404)

  • 1. Model averaging using fractional polynomials to estimate a safe level of exposure.
    Faes C; Aerts M; Geys H; Molenberghs G
    Risk Anal; 2007 Feb; 27(1):111-23. PubMed ID: 17362404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A probabilistic framework for non-cancer risk assessment.
    Chen JJ; Moon H; Kodell RL
    Regul Toxicol Pharmacol; 2007 Jun; 48(1):45-50. PubMed ID: 17166641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model averaging in microbial risk assessment using fractional polynomials.
    Namata H; Aerts M; Faes C; Teunis P
    Risk Anal; 2008 Aug; 28(4):891-905. PubMed ID: 18564995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Model uncertainty and risk estimation for experimental studies of quantal responses.
    Bailer AJ; Noble RB; Wheeler MW
    Risk Anal; 2005 Apr; 25(2):291-9. PubMed ID: 15876205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exposure imprecision on estimation of the benchmark dose.
    Budtz-Jørgensen E; Keiding N; Grandjean P
    Risk Anal; 2004 Dec; 24(6):1689-96. PubMed ID: 15660622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing experimental designs for benchmark dose calculations for continuous endpoints.
    Kuljus K; von Rosen D; Sand S; Victorin K
    Risk Anal; 2006 Aug; 26(4):1031-43. PubMed ID: 16948695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantitative methods of cancer risk assessment in exposure to chemicals].
    Szymczak W
    Med Pr; 2009; 60(3):215-21. PubMed ID: 19746890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation.
    Wheeler MW; Bailer AJ
    Risk Anal; 2007 Jun; 27(3):659-70. PubMed ID: 17640214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotonic Bayesian semiparametric benchmark dose analysis.
    Wheeler M; Bailer AJ
    Risk Anal; 2012 Jul; 32(7):1207-18. PubMed ID: 22385024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision of benchmark dose estimates for continuous (nonquantal) measurements of toxic effects.
    Gaylor DW; Chen JJ
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):19-23. PubMed ID: 8921542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent number of implants and implications in developmental toxicity.
    Dunson DB
    Biometrics; 1998 Jun; 54(2):558-69. PubMed ID: 9629644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of BMD models in quantitative evaluation of carcinogenic risk].
    Szymczak W
    Med Pr; 1998; 49(6):579-87. PubMed ID: 10204147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
    Gocke E; Müller L; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation.
    Royston P; Sauerbrei W
    Stat Med; 2003 Feb; 22(4):639-59. PubMed ID: 12590419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a critical dose level for risk assessment: developments in benchmark dose analysis of continuous endpoints.
    Sand S; von Rosen D; Victorin K; Filipsson AF
    Toxicol Sci; 2006 Mar; 90(1):241-51. PubMed ID: 16322076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A parametric model for detecting hormetic effects in developmental toxicity studies.
    Hunt DL; Bowman D
    Risk Anal; 2004 Feb; 24(1):65-72. PubMed ID: 15028001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.